Home

Gum Armory To adapt ipsen press release Severe grade aim

Press Releases - Ipsen UK
Press Releases - Ipsen UK

Ipsen to acquire exclusive rights to investigational ERK inhibitor as part  of its existing research collaboration with AGV Discovery | Liberi Group
Ipsen to acquire exclusive rights to investigational ERK inhibitor as part of its existing research collaboration with AGV Discovery | Liberi Group

Pharma News and Updates | Ipsen, BioMarin, AbbVie, BMS, GSK, Novartis
Pharma News and Updates | Ipsen, BioMarin, AbbVie, BMS, GSK, Novartis

Press Releases - Ipsen UK
Press Releases - Ipsen UK

IPSEN: Announces FDA Approval of Dysport® (abobotulinumtoxinA) for the  Treatment of Upper Limb Spasticity in Children, Excluding Cerebral Palsy |  FDA Reporter
IPSEN: Announces FDA Approval of Dysport® (abobotulinumtoxinA) for the Treatment of Upper Limb Spasticity in Children, Excluding Cerebral Palsy | FDA Reporter

Ipsen Adds Another Program Into Its Pre-Clinical R&D Oncology Pipeline  Through an Exclusive Worldwide Collaboration With Accent Therapeutics,  Targeting the RNA Modifying Protein, METTL3 | Business Wire
Ipsen Adds Another Program Into Its Pre-Clinical R&D Oncology Pipeline Through an Exclusive Worldwide Collaboration With Accent Therapeutics, Targeting the RNA Modifying Protein, METTL3 | Business Wire

Ipsen's quick fix backfires | Evaluate
Ipsen's quick fix backfires | Evaluate

Ipsen CEO David Loew is elected to EFPIA leadership; joins industry  partners to warn of impact of EU pharma legislation - Global
Ipsen CEO David Loew is elected to EFPIA leadership; joins industry partners to warn of impact of EU pharma legislation - Global

Ipsen NHS Study Published - IFOPA - International Fibrodysplasia Ossificans  Progressiva Association
Ipsen NHS Study Published - IFOPA - International Fibrodysplasia Ossificans Progressiva Association

Ipsen is officially recognized as a great place to work worldwide - Global
Ipsen is officially recognized as a great place to work worldwide - Global

Ipsen puts patients first
Ipsen puts patients first

Ipsen Inc. | Aviation Pros
Ipsen Inc. | Aviation Pros

Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor,  a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a  long-term global partnership
Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership

Ipsen - David Meek appointed as Chief Executive Officer of Ipsen http://www. ipsen.com/wp-content/uploads/2016/07/11-07-2016-PR-David-Meek-new-CEO-of- Ipsen.pdf | Facebook
Ipsen - David Meek appointed as Chief Executive Officer of Ipsen http://www. ipsen.com/wp-content/uploads/2016/07/11-07-2016-PR-David-Meek-new-CEO-of- Ipsen.pdf | Facebook

Ipsen Goes All In on Neuro with $1 Billion+ Deal For Exicure's  Oligonucleotides | BioSpace
Ipsen Goes All In on Neuro with $1 Billion+ Deal For Exicure's Oligonucleotides | BioSpace

06-01-2016-PR-Ipsen-Galderma-APAC-Dysport-Aesthetics
06-01-2016-PR-Ipsen-Galderma-APAC-Dysport-Aesthetics

Ipsen ships 18 furnaces in Q2, including 210,000-pound capacity vacuum  furnace | ASM International
Ipsen ships 18 furnaces in Q2, including 210,000-pound capacity vacuum furnace | ASM International

Ipsen: Patients Living with Spasticity Want Long-lasting Symptom Relief |  Business Wire
Ipsen: Patients Living with Spasticity Want Long-lasting Symptom Relief | Business Wire

Gebrüder Weiss takes over Ipsen Logistics' Air & Sea business | DC Velocity
Gebrüder Weiss takes over Ipsen Logistics' Air & Sea business | DC Velocity

Press releases
Press releases

Combined Shareholders' Meeting of 27 May 2021
Combined Shareholders' Meeting of 27 May 2021

Ipsen: a dynamic, fast-growing specialty care powerhouse
Ipsen: a dynamic, fast-growing specialty care powerhouse

Press Releases / Melissa Peebles
Press Releases / Melissa Peebles

FOP Fnd NL on X: "Ipsen Initiates Partial Clinical Hold for Palovarotene  IND120181 and IND135403 Studies ...for children under the age of 14 because  of some cases with early growth plate closure...
FOP Fnd NL on X: "Ipsen Initiates Partial Clinical Hold for Palovarotene IND120181 and IND135403 Studies ...for children under the age of 14 because of some cases with early growth plate closure...

Ipsen and Medetia join forces to accelerate early research in rare disease  - Global
Ipsen and Medetia join forces to accelerate early research in rare disease - Global

Press Releases - Ipsen UK
Press Releases - Ipsen UK